

Amendments to the Claims

This listing of claims will replace all previous versions and listings of claims in the application:

1-9 (canceled)

10. (currently amended) An isolated antibody which specifically binds to a polypeptide having at least 80% amino acid sequence identity to (a) a polypeptide of SEQ ID NO:592 or (b) a polypeptide encoded by the full length coding region of the nucleotide sequence of SEQ ID NO:591 according to Claim 7.

11. (previously presented) The antibody of Claim 10, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

12. (currently amended) A composition of matter comprising ~~(a) a polypeptide of Claim 7, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody of Claim 10 that binds to said polypeptide,~~ in combination with a carrier.

13. (previously presented) The composition of matter of Claim 12, wherein said carrier is a pharmaceutically acceptable carrier.

14. (currently amended) The composition of matter of Claim 13 comprising a therapeutically effective amount of the antibody of Claim 10 (a), (b), (c) or (d).

15. (currently amended) An article of manufacture, comprising: a container; a label on said container; and a composition of matter comprising ~~(a) a polypeptide of Claim 7, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody of Claim 10 that binds to said polypeptide,~~ contained within said container, wherein label on said container indicates that said composition of matter can be used for treating an immune related disease.

16-27. (canceled)